J&J Voluntarily Recalls Certain OTC Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

J&J Voluntarily Recalls Certain OTC Products


ePT--the Electronic Newsletter of Pharmaceutical Technology

In consultation with the US Food and Drug Administration, McNeil Consumer Healthcare, a division of McNeil-PPC, part of Johnson & Johnson (New Brunswick, NJ) is voluntarily recalling certain lots of over-the-counter (OTC) products in the Americas, the United Arab Emirates, and Fiji, according to a J&J press release.

J&J initiated the recall on Jan. 15, 2009, following an investigation of consumer reports of an unusual moldy, musty, or mildewlike odor that, in a small number of cases, was associated with temporary gastrointestinal events such as nausea, stomach pain, vomiting, or diarrhea.

The recalled products include various strengths and dosage forms of Benadryl, Motrin, Rolaids, Simply Sleep, St. Joseph Aspirin, and Tylenol. The full product recall list may be found here.

McNeil Consumer Healthcare determined that the reported uncharacteristic smell is caused by trace amounts of 2,4,6-tribromoanisole (TBA). The company said that this impurity can result from the breakdown of a chemical that is sometimes applied to wood in pallets that transport and store product-packaging materials. “The health effects of this chemical have not been well studied, but no serious events have been documented in the medical literature,” according to the J&J release.

In December 2009, McNeil Consumer Healthcare also recalled all lots of Tylenol Arthritis Pain 100 count with Ez-Open Cap for the same reason. “McNeil Consumer Healthcare has now applied broader criteria to identify and remove all product lots that it believes may have the potential to be affected, even if they have not been the subject of consumer complaints,” said J&J in the release. “In addition to the product recall, McNeil Consumer Healthcare is continuing [its] investigation into this issue and is taking further actions that include ceasing shipment of products produced using materials shipped on these wood pallets and requiring suppliers who ship materials to our plants to discontinue the use of these pallets.”

McNeil Consumer Healthcare will continue to closely monitor and evaluate the situation and consult with FDA. The company advises consumers who purchased product from the lots included in the recall to stop using the product and contact McNeil Consumer Healthcare for instructions on a refund or replacement.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Looking forward 10 years from now, what do you think will be the most significant change to drug development and manufacturing?
Fuller adoption of quality by design principles
Greater adoption of continuous manufacturing
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
The rise of biologic-based drugs in commercial product portfolios and pipelines
Greater adoption of the preferred provider model in outsourcing
Fuller adoption of quality by design principles
22%
Greater adoption of continuous manufacturing
7%
A stronger movement to personalized medicine and the use of diagnostics with traditional pharmaceuticals
35%
The rise of biologic-based drugs in commercial product portfolios and pipelines
30%
Greater adoption of the preferred provider model in outsourcing
7%
View Results
Jim MillerOutsourcing OutlookJim Miller Channeling Steve Jobs
Patricia Van ArnumIngredients InsiderPatricia Van ArnumSeeking Chemocatalytic and Biocatalytic Solutions
Nathan JessopIndustry InsiderNathan Jessop Taxing Times for French Pharma
Lynn D. TorbeckStatistical Solutions Lynn D. TorbeckRepresentative Sampling
Report on Recent and Upcoming Single-Use Meetings
ICH Q11 Reaches Harmonization, Implementation is Next
Digital Signatures Growing as a Result of Part 11
Single-Cell Genomics Advancing Molecular Biology
Putting FDA’s “Process Validation” Guidance into Action
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here